Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Secukinumab
Cosentyx
Routinely available
SMC ( SMC2592)
07/08/2024

Indication

For the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsu...

For the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.

Therapeutic Area

Skin

Status Description

Routinely available in line with national guidance

Formulation

150 mg or 300 mg solution for injection in pre-filled pen or pre-filled syringe

Comments

Link to Advice

SMC2592

Advice Published

12/02/2024

SMC Submission Type

Full

SMC Status

Restricted